For both BRCA1 and BRCA2 heterozygotes, the strength of the association was greater for ER-positive contralateral breast cancers compared with ER-negative contralateral breast cancers (in the case of BRCA1, even if the ER-negative PRS was used), although most of the confidence intervals overlapped. This evidence concerns the gene BRCA2 and breast cancer.